Oncology

Patients with newly diagnosed, locally advanced head and neck squamous cell carcinoma (HNSCC) may soon benefit from a major shift in treatment strategy, as phase III trial data show that perioperative pembrolizumab significantly improves outcomes when added to standard care.

Promising new data emerged on zongertinib, an investigational oral therapy targeting HER2 mutations in advanced non-small cell lung cancer (NSCLC), was presented at the AACR Annual Meeting 2025 in Chicago.

At the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, new data revealed that a liquid biopsy using circulating tumor DNA (ctDNA) could detect colorectal cancer recurrence significantly earlier than imaging, with ctDNA signals appearing up to 416 days before clinical detection.

At the AACR Annual Meeting 2025 in Chicago, researchers unveiled promising early results from a novel cell therapy that could reshape treatment options for patients with relapsed or refractory acute myeloid leukemia (AML).

Neoadjuvant immunotherapy using PD-1 blockade has demonstrated the potential to eliminate the need for surgery in patients with early-stage mismatch repair-deficient (dMMR) cancers, according to groundbreaking data presented at the AACR Annual Meeting 2025.

At the AACR 2025 Annual Meeting in Chicago, new data presented on the investigational agent zoldonrasib showed encouraging clinical activity in patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation.

Timely lung cancer diagnosis and treatment are essential for improved survival, but new research shows that patients with suspicious lung nodules continue to experience critical delays at multiple stages of care.

Patients undergoing spinal surgery for metastatic disease face a heightened risk of nonroutine discharge, often leading to increased healthcare costs and higher readmission rates.